Furthermore, EGFR mutant tumors respond poorly to immune checkpoint inhibitors [36,37,38,39]; this is attributed to factors such as lower tumor mutation burdens in EGFR mutant lung cancer [40], but this remains poorly understood. Here, EGFR is linked to neoplasm.